Diversity of Susceptibility to Unsaturated Fatty Acids in Enterococcus Strains and Their Synergistic Effects With Antibiotics
Microbiology and Immunology · 2026
DOI: 10.1111/1348-0421.70037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology and Immunology, 2026. Verfasst von Keijuro Ohdan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Fatty Acids, Unsaturated, Enterococcus. Die Arbeit nennt 49 Literaturangaben. Gefördert von: JST SPRING.
Abstract (Originalsprache)
Enterococci are commensal bacteria in humans that are found in the intestine, pharynx and oral cavity and sometimes cause opportunistic infections such as intra‐abdominal infections and bacteraemia. Several enterococcal species, especially E. faecium and E. faecalis , have become clinical problems as drug‐resistant bacteria, including vancomycin‐resistant Enterococci (VRE). Therefore, new antibacterial agents against enterococcal infections are needed. Because several fatty acids (FAs) have been reported to possess antibacterial activity, in this study, the effects of 3 unsaturated fatty acids on enterococci were evaluated using clinically isolated strains. Among the 3 fatty acids we tested, linoleic acid (LA) and palmitoleic acid (POA) exhibited antibacterial activity against E. faecalis and E. faecium . Next, we evaluated the antibacterial activities of the two FAs against 126 enterococcal clinical strains, including five different species. The minimum inhibitory concentration (MIC) of LA varied among bacterial species and strains (ranging from 37.5 to 1200 μM), while the MIC of POA was similar (ranging from 37.5 to 150 μM). Among species, E. faecium strains presented higher MICs than E. faecalis , E. avium and E. casseliflavus strains. In 6 VRE strains, the MICs of LA showed variable (150–1200 μM), whereas MICs of POA were constant at 75 μM. We subsequently investigated the combined effects of LA and POA with several antibiotics and found that LA had synergistic effects with β‐lactam, gentamicin, ciprofloxacin and vancomycin against E. faecalis and E. faecium strains, including VRE, whereas POA did not have a significant effect. Our results indicate the potential application of FAs for enterococcal infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
- Department of Bacteriology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
- Department of Oral Oncology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
- Department of Biological Endodontics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
ORCID-Profile: Souichi Yanamoto, Hitoshi Komatsuzawa
Förderung
- JST SPRING
Zitieren
APA
Ohdan, K., Asada, Y., Nishihama, S., Kawada-Matsuo, M., Shiba, H., Yanamoto, S., Aikawa, T., & Komatsuzawa, H. (2026). Diversity of Susceptibility to Unsaturated Fatty Acids in Enterococcus Strains and Their Synergistic Effects With Antibiotics. Microbiology and Immunology. https://doi.org/10.1111/1348-0421.70037
Vancouver
Ohdan K, Asada Y, Nishihama S, Kawada-Matsuo M, Shiba H, Yanamoto S, et al. Diversity of Susceptibility to Unsaturated Fatty Acids in Enterococcus Strains and Their Synergistic Effects With Antibiotics. Microbiology and Immunology. 2026. doi:10.1111/1348-0421.70037
BibTeX
@article{Ohdan2026,
author = {Ohdan, Keijuro and Asada, Yasuyuki and Nishihama, Saki and Kawada-Matsuo, Miki and Shiba, Hideki and Yanamoto, Souichi and Aikawa, Tomonao and Komatsuzawa, Hitoshi},
title = {Diversity of Susceptibility to Unsaturated Fatty Acids in Enterococcus Strains and Their Synergistic Effects With Antibiotics},
journal = {Microbiology and Immunology},
year = {2026},
doi = {10.1111/1348-0421.70037}
}
EUVIMED